NCT04203329Unknown不适用
A Multi-center, Prospective, Single Arm Registry to Evaluate Procedural Outcomes Using the Cardiva VASCADE MVP VVCS Closure Device After Catheter-based Atrial Fibrillation Interventions for Patients Who Are Discharged the Same Day.
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 700
- 试验地点
- 15
- 主要终点
- VASCADE MVP VVCS Procedure Success
研究概览
简要总结
A multi-center, prospective, single-arm post market registry, designed to collect both performance and complication outcomes when same day discharge is enabled by the study device, in sealing multiple femoral venous access sites at the completion of ablation procedures for atrial fibrillation with or without another arrhythmia, performed through 6 - 12 Fr inner diameter (maximum 15F OD) introducer sheaths.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pre-Operative Inclusion:
- •All subjects are required to meet the following inclusion criteria in order to be considered eligible for participation in this trial:
- •≥18 years of age;
- •Capable and willing to give informed consent;
- •Acceptable candidate for an elective, non-emergent catheter-based paroxysmal atrial fibrillation ablation procedure with or without another arrhythmia via the common femoral vein(s) using a 6 to 12 Fr inner diameter (max 15F OD) introducer sheath
- •Is accompanied by a person who will be available to assist the subject for 24 hours post-procedure and/or has access to emergency services;
- •Is willing/able to stay overnight at the hospital per physician discretion.
- •Able and willing to complete two follow-up contacts at 2-4 days and 15 (± 5) days post-procedure.
- •Acceptable candidate for emergent vascular surgery, and/or manual compression of the venous access site;
- •Intra-Operative Inclusion:
- •All criteria apply:
- •In the Investigator's opinion, the subject is a candidate for Same Day Discharge per protocol (e.g., no new pericardial effusion, post-procedure diuresis not needed, etc.).
- •Physician or designee will be on site for discharge evaluation.
- •Case completed in time for subject to be reasonably recovered and discharged according to protocol.
- •All femoral venous access sites are planned to be closed with the MVP
- •Initial subject eligibility will be determined based on pre-operative screening.
- •Final subject enrollment will be determined at the end the procedure, prior to closure, based on general intra-op exclusion criteria, as well as additional intraoperative criteria. Enrollment is thus determined intra-operatively, at the end of the case and just prior to closure.
排除标准
- •Pre-Operative Exclusion:
- •Subjects will be excluded from participating in this study if they meet any of the following criteria prior to initiation of the index procedure:
- •Advanced refusal of blood transfusion, if it should become necessary;
- •Active systemic infection, or cutaneous infection or inflammation in the vicinity of the groin;
- •Pre-existing immunodeficiency disorder and/or chronic use of high dose systemic steroids;
- •Known history of bleeding diathesis, coagulopathy, hypercoagulability, or current platelet count < 100,000 cells/mm3;
- •Severe co-existing morbidities, with a life expectancy of less than 12 months;
- •Currently involved in any clinical trial that may interfere with the outcomes of this study in the opinion of investigator;
- •Femoral arteriotomy in either limb with any of the following conditions:
- •access within < 10 days
- •any residual hematoma, significant bruising, or known associated vascular complications
- •use of a vascular closure device within the previous 30 days;
- •Femoral venotomy in either limb with any of the following conditions:
- •access within < 10 days
- •any residual hematoma, significant bruising, or known associated vascular complications
- •use of a vascular closure device
- •Any planned procedure involving femoral arterial or venous access in either limb within the next 30 days;
- •Any history of deep vein thrombosis, pulmonary embolism or thrombophlebitis;
- •Significant anemia with a hemoglobin level less than 10 g/dL or a hematocrit less than 30%;
- •Females who are pregnant, planning to become pregnant within 3 months of the procedure, or who are lactating;
- •Extreme morbid obesity (BMI greater than 45 kg/m2) or underweight (BMI less than 20 kg/m2);
- •Unable to routinely walk at least 20 feet without assistance;
- •Known allergy/adverse reaction to bovine derivatives;
- •Administration of low molecular weight heparin (LMWH) within 8 hours before or after the procedure;
- •Planned procedures or concomitant condition(s) that may extend ambulation attempts beyond routine ambulation and/or hospital discharge time (e.g., staged procedure, serious co-morbidity, uncontrolled obstructive sleep apnea, congestive heart failure), in the opinion of the Investigator.
- •Current diagnosis of persistent or permanent atrial fibrillation.
- •General Intra-op Exclusion Criteria:
- •Subjects will be excluded from participating in this study if any of the following exclusion criteria occur during the index procedure:
- •Any attempt at femoral arterial access during the procedure;
- •Any procedural complications that may extend routine recovery, ambulation and discharge times;
- •If the physician deems that a different method should be used to achieve hemostasis of the venous access sites, or that the subject should not attempt ambulation according to the protocol requirements;
- •All venous access sites must are subject to the following exclusion criteria, assessed immediately prior to enrollment:
- •Difficult insertion of procedural sheath or needle stick problems at the onset of the procedure (e.g., multiple stick attempts, accidental arterial stick with hematoma, "back wall stick", etc.) in any of the study veins;
- •A procedural sheath < 6 Fr or > 12 Fr in inner diameter is present at time of closure;
- •Venous access site location is noted to be "high", above the inguinal ligament (cephalad to lower half of the femoral head or the inferior epigastric vein origin from the external iliac vein);
- •Intra-procedural bleeding around sheath, or suspected intraluminal thrombus, hematoma, pseudoaneurysm, or AV fistula;
- •Length of the tissue tract, the distance between the anterior venous wall and skin, is estimated to be less than 2.5 cm.
- •Discharge Evaluation Criteria
- •Physician or designee must perform discharge evaluation.
- •Subject has successfully ambulated without bleeding from access site.
- •Subject has been able to void.
- •No clinically significant ECG findings.
- •Subject is accompanied by a responsible person who will be near them for the next 24 hours. Subjects must meet all Discharge Criteria in order to be eligible for same day discharge at physician discretion.
- •Group 2 Persistent A-Fib Pre-Operative Inclusion Criteria All subjects are required to meet the following inclusion criteria in order to be considered eligible for participation in this trial:
- •≥18 years of age;
- •Capable and willing to give informed consent;
- •Acceptable candidate for an elective, persistent atrial fibrillation ablation procedure;
- •Acceptable candidate planned for same day discharge;
- •Able and willing to complete two follow-up contacts at 2-4 days and 15 (± 5) days post-procedure.
- •Pre-Operative Exclusion Criteria Subjects will be excluded from participating in this study if they meet any of the following criteria prior to initiation of the index procedure:
- 另有 73 项未显示
结局指标
主要结局
VASCADE MVP VVCS Procedure Success
时间窗: 1 day
Patients do not require next day hospital intervention\* due to access site-related complications.
Major Complication Rate
时间窗: 15 Days +/- 5 Days
On a per-limb basis, the rate of combined major venous access site closure-related complications attributed directly to the closure method within 15 ± 5 days of discharge (i.e., "device-related" with no other likely attributable cause).
次要结局
- Device Success(intra-procedural)
- Same Day Procedure Success(1 day)
- Sustained VASCADE MVP VVCS Procedure Success(15 Days +/- 5 Days)
- Minor Complication Rate(15 Days +/- 5 Days)
研究者
研究点 (15)
Loading locations...
相似试验
终止
不适用
Post Market Observational, Prospective, Multi-center StudyEmphysemaNCT01806636Boston Scientific Corporation1,275
已完成
不适用
Cardiogenesis Transmyocardial Revascularization RegistryClass IV AnginaNCT01827319Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.203
已完成
不适用
Nellix® Registry Study: EVAS-GlobalSafety and Performance of the Nellix Endovascular Sealing SystemNCT02018744Endologix300
已完成
不适用
Cruz HBR Registry - Post-market Registry to Evaluate the Safety and Efficacy of the Supraflex Cruz StentCoronary Artery DiseaseNCT04138238Sahajanand Medical Technologies Limited1,200
已完成
不适用
Clinical Performance of the Globe® Mapping and Ablation System for the Treatment of Atrial FibrillationAtrial FibrillationNCT04954911Kardium Inc.6